Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors

Ciara C. O'Sullivan, Dominic H. Moon, Elise C. Kohn, Jung Min Lee

Research output: Contribution to journalReview article

60 Citations (Scopus)

Abstract

Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown clinical activity in patients with germline BRCA1/2 mutation (gBRCAm)-associated breast and ovarian cancers. Accumulating evidence suggests that PARPi may have a wider application in the treatment of cancers defective in DNA damage repair pathways, such as prostate, lung, endometrial, and pancreatic cancers. Several PARPi are currently in phase I/II clinical investigation, as single-agents and/or combination therapy in these solid tumors. Understanding more about the molecular abnormalities involved in BRCA-like phenotype in solid tumors beyond breast and ovarian cancers, exploring novel therapeutic trial strategies and drug combinations, and defining potential predictive biomarkers are critical to expanding the scope of PARPi therapy. This will improve clinical outcome in advanced solid tumors. Here, we briefly review the preclinical data and clinical development of PARPi, and discuss its future development in solid tumors beyond gBRCAm-associated breast and ovarian cancers.

Original languageEnglish (US)
Article numberArticle 42
JournalFrontiers in Oncology
Volume4 MAR
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Breast Neoplasms
Mutation
Neoplasms
Drug Combinations
Therapeutics
Endometrial Neoplasms
Pancreatic Neoplasms
DNA Repair
DNA Damage
Lung Neoplasms
Prostatic Neoplasms
Biomarkers
Poly(ADP-ribose) Polymerase Inhibitors
Phenotype

Keywords

  • BRCA mutation
  • BRCA-like
  • DNA damage repair pathway
  • Poly(ADP-ribose) polymerase inhibitors
  • solid tumors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Beyond breast and ovarian cancers : PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors. / O'Sullivan, Ciara C.; Moon, Dominic H.; Kohn, Elise C.; Lee, Jung Min.

In: Frontiers in Oncology, Vol. 4 MAR, Article 42, 01.01.2014.

Research output: Contribution to journalReview article

@article{106f9267ec7646078061bdeafc92b790,
title = "Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors",
abstract = "Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown clinical activity in patients with germline BRCA1/2 mutation (gBRCAm)-associated breast and ovarian cancers. Accumulating evidence suggests that PARPi may have a wider application in the treatment of cancers defective in DNA damage repair pathways, such as prostate, lung, endometrial, and pancreatic cancers. Several PARPi are currently in phase I/II clinical investigation, as single-agents and/or combination therapy in these solid tumors. Understanding more about the molecular abnormalities involved in BRCA-like phenotype in solid tumors beyond breast and ovarian cancers, exploring novel therapeutic trial strategies and drug combinations, and defining potential predictive biomarkers are critical to expanding the scope of PARPi therapy. This will improve clinical outcome in advanced solid tumors. Here, we briefly review the preclinical data and clinical development of PARPi, and discuss its future development in solid tumors beyond gBRCAm-associated breast and ovarian cancers.",
keywords = "BRCA mutation, BRCA-like, DNA damage repair pathway, Poly(ADP-ribose) polymerase inhibitors, solid tumors",
author = "O'Sullivan, {Ciara C.} and Moon, {Dominic H.} and Kohn, {Elise C.} and Lee, {Jung Min}",
year = "2014",
month = "1",
day = "1",
doi = "10.3389/fonc.2014.00042",
language = "English (US)",
volume = "4 MAR",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Beyond breast and ovarian cancers

T2 - PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors

AU - O'Sullivan, Ciara C.

AU - Moon, Dominic H.

AU - Kohn, Elise C.

AU - Lee, Jung Min

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown clinical activity in patients with germline BRCA1/2 mutation (gBRCAm)-associated breast and ovarian cancers. Accumulating evidence suggests that PARPi may have a wider application in the treatment of cancers defective in DNA damage repair pathways, such as prostate, lung, endometrial, and pancreatic cancers. Several PARPi are currently in phase I/II clinical investigation, as single-agents and/or combination therapy in these solid tumors. Understanding more about the molecular abnormalities involved in BRCA-like phenotype in solid tumors beyond breast and ovarian cancers, exploring novel therapeutic trial strategies and drug combinations, and defining potential predictive biomarkers are critical to expanding the scope of PARPi therapy. This will improve clinical outcome in advanced solid tumors. Here, we briefly review the preclinical data and clinical development of PARPi, and discuss its future development in solid tumors beyond gBRCAm-associated breast and ovarian cancers.

AB - Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown clinical activity in patients with germline BRCA1/2 mutation (gBRCAm)-associated breast and ovarian cancers. Accumulating evidence suggests that PARPi may have a wider application in the treatment of cancers defective in DNA damage repair pathways, such as prostate, lung, endometrial, and pancreatic cancers. Several PARPi are currently in phase I/II clinical investigation, as single-agents and/or combination therapy in these solid tumors. Understanding more about the molecular abnormalities involved in BRCA-like phenotype in solid tumors beyond breast and ovarian cancers, exploring novel therapeutic trial strategies and drug combinations, and defining potential predictive biomarkers are critical to expanding the scope of PARPi therapy. This will improve clinical outcome in advanced solid tumors. Here, we briefly review the preclinical data and clinical development of PARPi, and discuss its future development in solid tumors beyond gBRCAm-associated breast and ovarian cancers.

KW - BRCA mutation

KW - BRCA-like

KW - DNA damage repair pathway

KW - Poly(ADP-ribose) polymerase inhibitors

KW - solid tumors

UR - http://www.scopus.com/inward/record.url?scp=84898020932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898020932&partnerID=8YFLogxK

U2 - 10.3389/fonc.2014.00042

DO - 10.3389/fonc.2014.00042

M3 - Review article

C2 - 24616882

AN - SCOPUS:84898020932

VL - 4 MAR

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - Article 42

ER -